论文部分内容阅读
目的观察前列地尔联合西洛他唑治疗2型糖尿病(T2DM)合并下肢动脉病变(PAD)早期疗效。方法 86例T2DM合并PAD早期患者在血糖控制良好基础上(糖化血红蛋白<7.0),给予静脉滴注前列地尔20μg/天,共3周;同时口服西洛他唑100mg,2次/天,连续6个月,治疗前后分别监测无痛行走距离和最大行走距离、踝/肱指数(ABI)及患者自觉症状及体征的变化。结果联合治疗后患者无痛行走距离和最大行走距离、ABI均显著增加,间歇性跛行、下肢疼痛、麻木明显好转。结论前列地尔联合西洛他唑治疗2型糖尿病合并下肢动脉病变早期效果显著。
Objective To observe the early curative effect of alprostadil combined with cilostazol on type 2 diabetes mellitus (T2DM) complicated with arterial disease of lower extremities (PAD). Methods Eighty-six patients with T2DM complicated with early PAD were given glycemic hemoglobin (HbA1c) <7.0, and were given intravenous alprostadil 20μg / day for 3 weeks. Meanwhile, Cilostazol 100 mg twice daily for continuous 6 months before and after treatment were monitored painless walking distance and maximum distance traveled, ankle / brachial index (ABI) and patients with symptoms and signs of change. Results After treatment, painless walking distance and maximum walking distance were significantly increased in ABI patients. Intermittent claudication, lower extremity pain and numbness improved obviously. Conclusions The combination of alprostadil and cilostazol has a good early effect in the treatment of type 2 diabetes mellitus with arterial disease of the lower extremities.